NAVANA PHARMACEUTICALS PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113 BDT | +2.82% |
|
+7.52% | +33.89% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 4.76B 40.78M 55.58M | Sales 2023 | 5.71B 48.9M 66.64M | Capitalization | 12.55B 108M 147M |
|---|---|---|---|---|---|
| Net income 2022 | 274M 2.35M 3.2M | Net income 2023 | 357M 3.06M 4.17M | EV / Sales 2022 * | - |
| Net Debt 2022 | 2.8B 23.98M 32.69M | Net Debt 2023 | 3.72B 31.88M 43.45M | EV / Sales 2023 | 2.85 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
32.5
x | Employees | 4,143 |
| Yield 2022 * |
-
| Yield 2023 |
1.11% | Free-Float | 99% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.82% | ||
| 1 week | +7.52% | ||
| Current month | +31.70% | ||
| 1 month | +26.26% | ||
| 3 months | +20.60% | ||
| 6 months | +35.49% | ||
| Current year | +33.89% |
1 week
104.00
118.90
1 month
82.50118.90
Current year
81.90118.90
1 year
78.30122.40
3 years
26.40132.00
5 years
26.40132.00
10 years
26.40132.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 20-11-24 | |
| Director of Finance/CFO | 42 | 13-03-24 | |
| Director of Finance/CFO | 54 | 20-11-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 51 | 20-02-11 | |
| Chief Executive Officer | 63 | 20-11-24 | |
| Director/Board Member | 44 | 20-11-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 113 | +2.82% | 1,614,217 |
| 24-05-14 | 109.9 | -2.92% | 1,483,323 |
| 24-05-13 | 113.2 | -0.35% | 1,771,750 |
| 24-05-12 | 113.6 | +9.97% | 3,504,575 |
| 24-05-09 | 103.3 | -1.71% | 1,407,826 |
End-of-day quote Dhaka S.E., May 14, 2024
More quotes
Navana Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing, marketing, and distribution of pharmaceutical products for human and animal health products and sales of the produced items in the domestic and foreign market. The Company is engaged in manufacturing, marketing and distribution of generic pharmaceuticals finished products, which includes human drugs dosages form like tablet, capsule, powder for suspension, cream, ointment, powder, injection, eye and nasal drop, liquid, sachet products, oral solution, veterinary drugs dosages form like vaccine, bolus, liquid, injection, water soluble powder and premix. Its products include Olopatadine, Cefixime, Levamlodipine, Nepafenac, L-Lysine Monohydrochloride, Benzalkonium Chloride (BKC), Zinc sulfate monohydrate USP, Tilmicosin Phosphate INN, Ketoprofen, Butaphosphan INN & Cyanocobalamin BP (Vitamin B12), New Castle Disease+Infectious Bursal Disease virus vaccine and others.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +33.89% | 104M | |
| +35.01% | 709B | |
| +30.96% | 595B | |
| -2.60% | 367B | |
| +20.83% | 334B | |
| +5.69% | 289B | |
| +14.42% | 239B | |
| +9.41% | 211B | |
| -4.29% | 203B | |
| +10.77% | 171B |
- Stock Market
- Equities
- NAVANAPHAR Stock